LivaNova Q1 Revenue Climbs 14.3%, Boosts 2026 Outlook and Secures Aura6000 Approval
LIVN•LivaNova posted Q1 revenue of $362.3m, up 14.3% reported (11.1% cc), and delivered GAAP EPS of $0.40 and adjusted EPS of $0.98. It raised 2026 revenue growth guidance to 7.0%–8.0% cc and adjusted EPS outlook to $4.20–$4.30 while winning FDA approval for its aura6000™ hypoglossal nerve stimulation system.
1. Q1 Financial Results
LivaNova reported first-quarter 2026 revenue of $362.3 million, a 14.3% increase on a reported basis and 11.1% on a constant-currency basis. GAAP diluted EPS reached $0.40 versus a prior-year loss of $6.01, with adjusted diluted EPS of $0.98 up from $0.88. Operating cash flow was $15.2 million and adjusted free cash flow totaled $3.8 million.
2. Segment Performance
Cardiopulmonary revenue rose 18.3% to $208.7 million driven by Essenz™ Perfusion System sales, strong consumables demand and favorable pricing. Neuromodulation revenue grew 9.3% to $151.8 million on higher implant volumes and realized price improvements across all regions.
3. Guidance Update
The company increased its full-year 2026 revenue growth outlook by 100 basis points to 7.0%–8.0% on a constant-currency basis and lifted its adjusted diluted EPS range by $0.05 at midpoint to $4.20–$4.30, maintaining free cash flow guidance at $160–$180 million.
4. FDA Approval and OSA Strategy
LivaNova secured FDA premarket approval for its aura6000™ hypoglossal nerve stimulation system for moderate to severe obstructive sleep apnea, marking the first device without a concentric collapse warning or drug-induced sleep endoscopy requirement. In April, 12-month OSPREY trial data demonstrated sustained clinical responses, supporting entry into the high-margin OSA market.
